Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First
Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable